-
Machine Learning Predicts How DNA Breaks Under CRISPR
Bio-IT World | In a study published yesterday in Nature, researchers created a machine-learning model—inDelphi—that predicts how human and mouse cells will respond to CRISPR-induced breaks in DNA.
Nov 8, 2018
-
NVMe: Powering Genomics And Life Sciences
Bio-IT World Contributed Commentary | Most organizations require high speed computing capabilities. NVMe delivers this capability to businesses by tapping into the power and speed of flash technology and increasing data processing speeds by up to 100 times when compared to spinning disk media.
Nov 7, 2018
-
A Billionaires Dying Wish A $10 Million Prize To Fight Brain Diseases
Forbes | Named for late billionaire Richard Rainwater, the Rainwater Prize Program has launched to help find a cure for a rare brain disease.
Nov 6, 2018
-
In conversation with… Harold Varmus
Mosaic | Alok Jha talks to Harold Varmus, Nobel Prize-winning cancer researcher and current Director of the US National Cancer Institute.
Nov 6, 2018
-
Illumina Acquires PacBio, Discusses Future In Investor Call
Bio-IT World | Yesterday Illumina announced its intention to acquire Pacific Biosciences. Both companies presented the details and took questions during an investor call.
Nov 2, 2018
-
New Head For Renamed Icahn Institute At Mount Sinai
Bio-IT World | Mount Sinai has named a new head for its Icahn Institute, and renamed the effort the Icahn Institute for Data Science and Genomic Technology. Adam Margolin will lead the new enterprise-wide program, whose 10-year plan includes 55 new faculty and staff, new computational infrastructure, and an educational program to train master’s students and PhDs in biomedical data science.
Nov 2, 2018
-
Illumina Buys PacBio For $1.2 Billion
Bio-IT World News Brief | Illumina and Pacific Biosciences today announced they have signed an agreement for Illumina to acquire Pacific Biosciences at a price of $8.00 per Pacific Biosciences share in an all-cash transaction. This price represents a premium of 71% to Pacific Biosciences’ 30 trading day volume weighted average share price as of the market close on October 31st, 2018, and a total enterprise value of approximately $1.2 billion on a fully diluted basis.
Nov 1, 2018
-
23andMe Test Cleared To Help Patients Determine How Well Drugs May Work For Them
STAT | The genetic test is the first of its kind authorized by the Food and Drug Administration for direct-to-consumer marketing.
Nov 1, 2018


